eCite Digital Repository

The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation


Dargaville, PA and Kamlin, COF and De Paoli, AG and Carlin, JB and Orsini, F and Soll, RF and Davis, PG, The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation, BMC Paediatrics, 14, (1) Article 213. ISSN 1471-2431 (2014) [Refereed Article]


Copyright Statement

Copyright 2014 The Authors-This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, (CC BY 4.0). Which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

DOI: doi:10.1186/1471-2431-14-213


BACKGROUND: It is now recognized that preterm infants ≤28 weeks gestation can be effectively supported from the outset with nasal continuous positive airway pressure. However, this form of respiratory therapy may fail to adequately support those infants with significant surfactant deficiency, with the result that intubation and delayed surfactant therapy are then required. Infants following this path are known to have a higher risk of adverse outcomes, including death, bronchopulmonary dysplasia and other morbidities. In an effort to circumvent this problem, techniques of minimally-invasive surfactant therapy have been developed, in which exogenous surfactant is administered to a spontaneously breathing infant who can then remain on continuous positive airway pressure. A method of surfactant delivery using a semi-rigid surfactant instillation catheter briefly passed into the trachea (the "Hobart method") has been shown to be feasible and potentially effective, and now requires evaluation in a randomised controlled trial.

METHODS/DESIGN: This is a multicentre, randomised, masked, controlled trial in preterm infants 25-28 weeks gestation. Infants are eligible if managed on continuous positive airway pressure without prior intubation, and requiring FiO2 ≥ 0.30 at an age ≤6 hours. Randomisation will be to receive exogenous surfactant (200 mg/kg poractant alfa) via the Hobart method, or sham treatment. Infants in both groups will thereafter remain on continuous positive airway pressure unless intubation criteria are reached (FiO2 ≥ 0.45, unremitting apnoea or persistent acidosis). Primary outcome is the composite of death or physiological bronchopulmonary dysplasia, with secondary outcomes including incidence of death; major neonatal morbidities; durations of all modes of respiratory support and hospitalisation; safety of the Hobart method; and outcome at 2 years. A total of 606 infants will be enrolled. The trial will be conducted in >30 centres worldwide, and is expected to be completed by end-2017.

DISCUSSION: Minimally-invasive surfactant therapy has the potential to ease the burden of respiratory morbidity in preterm infants. The trial will provide definitive evidence on the effectiveness of this approach in the care of preterm infants born at 25-28 weeks gestation.

Item Details

Item Type:Refereed Article
Keywords:Bronchopulmonary dysplasia; Continuous positive airway pressure; Infant; Preterm; Pulmonary surfactants; Respiratory distress syndrome
Research Division:Biomedical and Clinical Sciences
Research Group:Paediatrics
Research Field:Paediatrics not elsewhere classified
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Dargaville, PA (Professor Peter Dargaville)
UTAS Author:De Paoli, AG (Dr Tony De Paoli)
ID Code:94577
Year Published:2014
Web of Science® Times Cited:47
Deposited By:Menzies Institute for Medical Research
Deposited On:2014-09-11
Last Modified:2017-11-06
Downloads:293 View Download Statistics

Repository Staff Only: item control page